Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice

Microbial network disturbances in relapsing refractory Crohn’s disease

(2019) Bahtiyar Yilmaz et al.   NATURE MEDICINE

Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease

(2019) Bram Verstockt et al.   EBioMedicine

Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients with Inflammatory Bowel Diseases

(2019) Konrad Aden et al.   GASTROENTEROLOGY

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

(2019) Nicholas A Kennedy et al.   Lancet Gastroenterology & Hepatology

Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease

(2018) A. Barré et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials

(2018) Siddharth Singh et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study

(2018) Marco Vincenzo Lenti et al.   DIGESTIVE AND LIVER DISEASE

Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease

(2018) Elisa K. Boden et al.   DIGESTIVE DISEASES AND SCIENCES

Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-label Trial of Patients With Ulcerative Colitis

(2018) Shannon E. Telesco et al.   GASTROENTEROLOGY

Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD

(2018) Renaud Gaujoux et al.   GUT

Genetic Markers Predict Primary Nonresponse and Durable Response to Anti–Tumor Necrosis Factor Therapy in Ulcerative Colitis

(2018) Kristin E Burke et al.   INFLAMMATORY BOWEL DISEASES

How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease

(2018) Samuele Naviglio et al.   Expert Review of Gastroenterology & Hepatology

Inflammatory bowel disease: towards a personalized medicine

(2018) Mathurin Flamant et al.   Therapeutic Advances in Gastroenterology

Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn’s Disease

(2018) Belén Beltrán et al.   DIGESTIVE DISEASES

Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

(2018) María Chaparro et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy

(2018) Toer W. Stevens et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients

(2018) Igor Vladimirovich Obraztsov et al.   INFLAMMATORY BOWEL DISEASES

Clinical usefulness of proteomics in inflammatory bowel disease: A comprehensive review

(2018) Javier P Gisbert et al.   Journal of Crohns & Colitis

Ustekinumab en el tratamiento de la enfermedad de Crohn

(2017) Javier P. Gisbert et al.   Gastroenterologia y Hepatologia

Molecular imaging of mucosal α4β7 integrin expression with the fluorescent anti-adhesion antibody vedolizumab in Crohn’s disease

(2017) Timo Rath et al.   GASTROINTESTINAL ENDOSCOPY

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study

(2017) Yoram Bouhnik et al.   GUT

Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

(2017) Carlos Taxonera et al.   INFLAMMATORY BOWEL DISEASES

Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience

(2017) Uri Kopylov et al.   INFLAMMATORY BOWEL DISEASES

Can We Predict the Efficacy of Anti-TNF-α Agents?

(2017) Loris Lopetuso et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy

(2017) D. G. Ribaldone et al.   IRISH JOURNAL OF MEDICAL SCIENCE

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study

(2017) Lauren Beswick et al.   Journal of Crohns & Colitis

Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease

(2017) Nathaniel R West et al.   NATURE MEDICINE

Clinical Significance of Bmi1 Expression in Inflammatory Bowel Disease

(2017) Mitsunari Yamada et al.   ONCOLOGY

Pharmacogenetic biomarkers of response in Crohn’s disease

(2017) T M Linares-Pineda et al.   PHARMACOGENOMICS JOURNAL

Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy

(2017) S Bank et al.   PHARMACOGENOMICS JOURNAL

Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn’s disease

(2017) Thomas Billiet et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Ustekinumab use in Crohn’s disease: a Canadian tertiary care centre experience

(2017) Astrid-Jane Greenup et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease

(2017) Uri Netz et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease

(2017) Azade Amini Kadijani et al.   Clinical and Translational Gastroenterology

The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease

(2016) N. Narula et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease

(2016) N. To et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients

(2016) L. Angelison et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study

(2016) D. C. Baumgart et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases

(2016) S. Bek et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study

(2016) A. Stallmach et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn’s Disease

(2016) Grant E Barber et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

(2016) Parambir S Dulai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents

(2016) Pauline Wils et al.   Clinical Gastroenterology and Hepatology

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

(2016) Aurelien Amiot et al.   Clinical Gastroenterology and Hepatology

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis

(2016) Gaik W. Tew et al.   GASTROENTEROLOGY

Patients with Refractory Crohnʼs Disease Successfully Treated with Ustekinumab

(2016) Kimberly A. Harris et al.   INFLAMMATORY BOWEL DISEASES

Role of Vitamin D in Infliximab-induced Remission in Adult Patients with Crohnʼs Disease

(2016) Krista M. Reich et al.   INFLAMMATORY BOWEL DISEASES

Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy

(2016) Valeria Caneparo et al.   INFLAMMATORY BOWEL DISEASES

Ustekinumab for the Treatment of Refractory Crohnʼs Disease

(2016) Sam Khorrami et al.   INFLAMMATORY BOWEL DISEASES

Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease

(2016) Namita Singh et al.   INFLAMMATORY BOWEL DISEASES

Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition

(2016) Maria K. Magnusson et al.   Journal of Crohns & Colitis

Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohn’s Disease

(2016) Peter Brown et al.   Journal of Crohns & Colitis

Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis

(2016) Iris Detrez et al.   Journal of Crohns & Colitis

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

(2016) Fernando Gomollón et al.   Journal of Crohns & Colitis

Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients

(2016) Marisa Iborra et al.   JOURNAL OF GASTROENTEROLOGY

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Prospective Pharmacogenomic Study of Crohn's Disease Patients during Routine Therapy with Anti-TNF-α Drug Adalimumab: Contribution ofATG5,NFKB1,andCRPGenes to Pharmacodynamic Variability

(2016) Matjaž Deželak et al.   OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-α antibodies in ulcerative colitis

(2016) Yukihiro Morita et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study

(2016) Marta Maia Bosca-Watts et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy

(2016) Angela C Baird et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study

(2016) Chang Hwan Choi et al.   YONSEI MEDICAL JOURNAL

Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease

(2016) Uri Kopylov et al.   Therapeutic Advances in Gastroenterology

Does Smoking Reduce Infliximab’s Effectiveness against Crohn’s Disease?

(2016) Neeraj Narula et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study

(2015) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONICpost hocanalysis

(2015) J.-F. Colombel et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Cultured blood T-cell responses predict anti-TNF therapy response in patients with ulcerative colitis

(2015) M. K. Magnusson et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed

(2015) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management

(2015) N. S. Ding et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

(2015) L Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis

(2015) Maria Theresa Arias et al.   Clinical Gastroenterology and Hepatology

Vedolizumab en el tratamiento de la enfermedad de Crohn

(2015) Javier P. Gisbert et al.   Gastroenterologia y Hepatologia

The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study

(2015) Andres J Yarur et al.   GUT

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients

(2015) Edward Shelton et al.   INFLAMMATORY BOWEL DISEASES

A Matrix-based Model Predicts Primary Response to Infliximab in Crohn’s Disease

(2015) Thomas Billiet et al.   Journal of Crohns & Colitis

Response to Infliximab in Crohn’s Disease: Genetic Analysis Supporting Expression Profile

(2015) Luz María Medrano et al.   MEDIATORS OF INFLAMMATION

Genetic polymorphism inATG16L1gene influences the response to adalimumab in Crohn's disease patients

(2015) Silvo Koder et al.   PHARMACOGENOMICS

Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy

(2015) Rahil Dahlén et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

pANCA Positivity Predicts Lower Clinical Response to Infliximab Therapy among Patients with IBD

(2015) Douglas L. Nguyen et al.   SOUTHERN MEDICAL JOURNAL

Genetic Polymorphisms ofIL-17FandTRAF3IP2Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn’s Disease

(2015) Shigetoshi Urabe et al.   Biomed Research International

Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease

(2014) R. W. Stidham et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early Intervention with Adalimumab May Contribute to Favorable Clinical Efficacy in Patients with Crohn's Disease

(2014) Jun Miyoshi et al.   DIGESTION

Physiological Intermolecular Modification Spectroscopy for the Prediction of Response to Anti-Tumor Necrosis Factor Therapy in Patients with Inflammatory Bowel Diseases

(2014) Pierre Eftekhari et al.   DIGESTIVE DISEASES

Molecular Patterns in Human Ulcerative Colitis and Correlation with Response to Infliximab

(2014) Brendan Halloran et al.   INFLAMMATORY BOWEL DISEASES

Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease

(2014) Iris Dotan et al.   INFLAMMATORY BOWEL DISEASES

Incidence and Predictors of Clinical Response, Re-induction Dose, and Maintenance Dose Escalation with Certolizumab Pegol in Crohnʼs Disease

(2014) Adam C. Stein et al.   INFLAMMATORY BOWEL DISEASES

Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature

(2014) Yael Haberman et al.   JOURNAL OF CLINICAL INVESTIGATION

Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience

(2014) U. Kopylov et al.   Journal of Crohns & Colitis

Smoking and Early Infliximab Response in Crohn's Disease: a Meta-analysis

(2014) S. Inamdar et al.   Journal of Crohns & Colitis

Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients

(2014) Charlotte P. Peters et al.   Journal of Crohns & Colitis

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

(2014) Séverine Vermeire et al.   LANCET

In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease

(2014) Raja Atreya et al.   NATURE MEDICINE

Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease

(2014) S Bank et al.   PHARMACOGENOMICS JOURNAL

Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn’s disease

(2014) Diamantis Thomas   WORLD JOURNAL OF GASTROENTEROLOGY

Optimizing anti-TNF treatments in inflammatory bowel disease

(2013) Shomron Ben-Horin et al.   AUTOIMMUNITY REVIEWS

Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment

(2013) Gordon W. Moran et al.   Clinical Gastroenterology and Hepatology

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease

(2013) Jean–Frédéric Colombel et al.   Clinical Gastroenterology and Hepatology

Severe Disease Activity and Cytomegalovirus Colitis Are Predictive of a Nonresponse to Infliximab in Patients with Ulcerative Colitis

(2013) Sang Hyoung Park et al.   DIGESTIVE DISEASES AND SCIENCES

Adalimumab for Crohn’s disease after infliximab treatment failure

(2013) Wei Da et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Role of TNFRSF1B polymorphisms in the response of Crohn’s disease patients to infliximab

(2013) L.M. Medrano et al.   HUMAN IMMUNOLOGY

FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity

(2013) Rintaro Moroi et al.   IMMUNOGENETICS

Genetic polymorphisms of tumour necrosis factor alpha (TNF-α) promoter gene and response to TNF-α inhibitors in Spanish patients with inflammatory bowel disease

(2013) R. López-Hernández et al.   International Journal of Immunogenetics

Serum protein profile of Crohn's disease treated with infliximab

(2013) Maria Gazouli et al.   Journal of Crohns & Colitis

High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment

(2013) Fernando Magro et al.   Journal of Crohns & Colitis

Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study

(2013) Kang-Moon Lee et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Towards personalized care in IBD

(2013) Mark E. Gerich et al.   Nature Reviews Gastroenterology & Hepatology

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis

(2013) Qiang Tong et al.   PHARMACOGENOMICS

The challenges of stratifying patients for trials in inflammatory bowel disease

(2013) Paolo Biancheri et al.   TRENDS IN IMMUNOLOGY

C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I

(2012) W. Reinisch et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study

(2012) F. Zorzi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease

(2012) C. Steenholdt et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn’s disease and ulcerative colitis

(2012) Diana Lacruz-Guzmán et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease

(2012) Amit Assa et al.   Journal of Crohns & Colitis

Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome

(2012) Orlando García-Bosch et al.   Journal of Crohns & Colitis

Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis

(2012) Renathe Rismo et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Crohn’s disease genotypes of patients in remissionvsrelapses after infliximab discontinuation

(2012) Cathy Lu   WORLD JOURNAL OF GASTROENTEROLOGY

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

(2011) L. S. Kiss et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial

(2011) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

(2011) Matthias Jürgens et al.   Clinical Gastroenterology and Hepatology

Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials

(2011) Adedigbo A. Fasanmade et al.   CLINICAL THERAPEUTICS

Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience

(2011) José Ignacio Fortea-Ormaechea et al.   Gastroenterologia y Hepatologia

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

(2011) A.A. Fasanmade et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience

(2011) Michael B. Sprakes et al.   Journal of Crohns & Colitis

Genetic and genomic predictors of anti-TNF response

(2011) Rita Prajapati et al.   PHARMACOGENOMICS

NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report

(2011) M. Barreiro-de Acosta et al.   REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn’s disease

(2010) H. MATSUKURA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy and Hospitalization

(2010) Abderrahim Oussalah et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?

(2010) Geert R D'Haens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Disease Activity, ANCA and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis

(2010) Matthias Jürgens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data

(2010) Stefan Schreiber et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn’s Disease

(2010) Cristina Nichita et al.   DIGESTION

Peripheral regulatory T cells and serum transforming growth factor-β: Relationship with clinical response to infliximab in Crohnʼs disease

(2010) Antonio Di Sabatino et al.   INFLAMMATORY BOWEL DISEASES

Predictive value of epithelial gene expression profiles for response to infliximab in Crohnʼs disease‡

(2010) Ingrid Arijs et al.   INFLAMMATORY BOWEL DISEASES

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab

(2009) C. MA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis

(2009) Trine Olsen et al.   CYTOKINE

Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis

(2009) William J. Sandborn et al.   GASTROENTEROLOGY

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis

(2009) I. Arijs et al.   GUT

Genome wide association (GWA) predictors of anti-TNFα therapeutic responsiveness in pediatric inflammatory bowel disease

(2009) Marla C. Dubinsky et al.   INFLAMMATORY BOWEL DISEASES

Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease

(2009) Corey A. Siegel et al.   Therapeutic Advances in Gastroenterology

Proteomics for prediction and characterization of response to infliximab in Crohn's disease: A pilot study

(2008) Marie-Alice Meuwis et al.   CLINICAL BIOCHEMISTRY

Predicting Factors of Fistula Healing and Clinical Remission After Infliximab-Based Combined Therapy for Perianal Fistulizing Crohn’s Disease

(2008) David Tougeron et al.   DIGESTIVE DISEASES AND SCIENCES

Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response

(2008) Yago González-Lama et al.   Gastroenterologia y Hepatologia

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

Long-term outcome after infliximab for refractory ulcerative colitis

(2008) Marc Ferrante et al.   Journal of Crohns & Colitis

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET